Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US clinical practice.

Alicia K. Morgans,Osama E. Rahma,Shivani K. Mhatre,Ching-Yi Chuo,Jessica Davies,Jorge Martinalbo,Nicole N. Davarpanah,Russell K. Pachynski

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US clinical practice.

2019

Alicia K. Morgans
Osama E. Rahma
Shivani K. Mhatre
Ching-Yi Chuo
Jessica Davies
Jorge Martinalbo
Nicole N. Davarpanah
Russell K. Pachynski

4526Background: Approval of anti–PD-L1/anti–PD-1 CPI agents has changed the mUC tx landscape, but real-world (RW) tx patterns are not well described. Here, we describe pt characteristics, time on t...

Keywords:

Clinical Practice
Pathology
Cancer
Oncology
Medicine
Internal medicine
locally advanced
urothelial cancer
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations